| 维持性血透患者口服l，25（0H）2D3的治疗观察 |
| |
| 引用本文： | 郑尘非,刘毅,徐玉兰.维持性血透患者口服l，25（0H）2D3的治疗观察[J].浙江临床医学,2003,5(6):416-417. |
| |
| 作者姓名： | 郑尘非 刘毅 徐玉兰 |
| |
| 作者单位： | 325000,温州医学院附属第一医院血液净化中心 |
| |
| 摘 要： | 目的观察维持性血透患者的继发性甲状旁腺功能亢进(
SHPT)不同剂量 1, 25( OH) 2D3治疗效果.方法对维持性血透的 SHPT患者根据其血清免疫反应性甲状旁腺激素(
iPTH)水平分 2组.小剂量组 1, 25( OH) 2D3, 0.25ug口服, 1次 /d和大剂量组 1,
25( OH) 2D3, 3.0ug口服, 2次 /周.分别观察两组治疗前后血清 iPTH、血钙、磷以及伴随的临床症状.结果小剂量组治疗后血清
iPTH水平较治疗前有明显下降 (262.76± 197.81)pg/MLvs(191.81±
144.74)pg/ML,p<0.05],血钙上升、血磷下降 (p<0.01).大剂量组治疗后血清
iPTH水平明显下降 (504.14± 387.01)pg/MLvs(182.56± 179.47)pg/ML,p<0.01],骨痛、皮肤瘙痒等症状明显减轻.结论口服
1, 25( OH) 2D3治疗维持性血透患者的 SHPT是有效的.
|
| 关 键 词： | 维持性血液透析 口服 l，25（0H）2D3 治疗 继发性甲状旁腺功能亢进 慢性肾功能衰竭 小剂量 大剂量 |
Therapy effect of 1,25- (OH)2 D3 on secondary hyperparathyroidism (SHPT) caused by maintenance hemodialysis |
| |
| Zheng Chengfei,et al.Therapy effect of 1,25- (OH)2 D3 on secondary hyperparathyroidism (SHPT) caused by maintenance hemodialysis[J].Zhejiang Clinical Medical Journal,2003,5(6):416-417. |
| |
| Authors: | Zheng Chengfei |
| |
| Abstract: | Objective To investigate the therapy effect of different dosage of 1,25-(OH)2D3 on secondary hyperparathyroidism(SHPT) caused by maintenance hemodialysis. Method Patient of SHPT who need maintenance hemodialysis were divided into 2 groups according to the serum level parathormone(PTH). Patients of group I took 1,25-(OH)2D3 orally at a dosage of 0.25ug/d. Patients of group II took 1,25-(OH)2D3orally at a dosage of 3.0ug/3d.The serum level of parathormone, calcium, phosphorum and concomitant clinical symptom were then observed. Result Group I showed notable decline of PTH and phosphorum and notable increase of calcium. Group II showed notable decline of PTH and alleviation of concomitant clinical symptom such as osteodynia and Itch of skin. Conclusion Oral vitD3(1,25) is a effect therapy for SHPT caused by maintenance hemodialysis. |
| |
| Keywords: | Hemodialysis Secondary hyperparathyroidism 1 25-(OH)2 D3 |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
